Gallagher’s appointment demonstrates the Company’s commitment to building a world-class intellectual property portfolio
Dr. Gannon will oversee and manage regulatory matters for the Company’s upcoming clinical trials, including its lead drug candidate in combination with Tagrisso® for which Fast Track Designation was received earlier this year.
Companies are optimizing nonviral delivery methods for commercial use
Designed and Secured by Barsec